HC Wainwright set a $17.00 price objective on ADMA Biologics (NASDAQ:ADMA) in a report issued on Friday. The brokerage currently has a buy rating on the biotechnology company’s stock.

“Our price target of $3/share is based on a discounted cash flow analysis (2018-2026) using a 12% discount rate and 2% growth rate, in line with the expected discount and growth parameters of a development-stage drug company. Risks to our investment thesis and target price include: (1) failure in clinical studies; (2) failure to secure regulatory approval; and (3) smaller than anticipated commercial opportunity due to market size, competition and pricing. Bellerophon Therapeutics, Inc.”,” the firm’s analyst commented.

Get ADMA Biologics alerts:

A number of other equities analysts have also commented on ADMA. Oppenheimer initiated coverage on shares of ADMA Biologics in a research report on Thursday, July 12th. They set a buy rating and a $13.00 price target on the stock. Maxim Group raised their target price on shares of ADMA Biologics from $10.00 to $12.00 and gave the company a buy rating in a report on Thursday, July 26th. ValuEngine raised shares of ADMA Biologics from a hold rating to a buy rating in a report on Thursday, July 26th. Chardan Capital started coverage on shares of ADMA Biologics in a report on Monday, July 30th. They issued a buy rating and a $10.00 target price on the stock. Finally, BidaskClub raised shares of ADMA Biologics from a hold rating to a buy rating in a report on Thursday, August 2nd. Eight equities research analysts have rated the stock with a buy rating, The stock currently has an average rating of Buy and a consensus price target of $11.58.

NASDAQ:ADMA traded down $0.48 during mid-day trading on Friday, reaching $5.26. 177,456 shares of the company’s stock were exchanged, compared to its average volume of 226,392. ADMA Biologics has a one year low of $2.10 and a one year high of $6.96. The firm has a market cap of $266.97 million, a price-to-earnings ratio of -2.75 and a beta of 2.28. The company has a debt-to-equity ratio of 0.79, a quick ratio of 8.88 and a current ratio of 10.65.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.02). ADMA Biologics had a negative return on equity of 89.78% and a negative net margin of 119.34%. The business had revenue of $4.23 million for the quarter, compared to the consensus estimate of $5.39 million. Sell-side analysts anticipate that ADMA Biologics will post -1.36 EPS for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of ADMA. BlackRock Inc. boosted its stake in shares of ADMA Biologics by 2,295.0% in the 2nd quarter. BlackRock Inc. now owns 970,839 shares of the biotechnology company’s stock valued at $4,378,000 after purchasing an additional 930,303 shares in the last quarter. Stonepine Capital Management LLC acquired a new stake in shares of ADMA Biologics in the 2nd quarter valued at approximately $3,751,000. Millennium Management LLC boosted its stake in shares of ADMA Biologics by 305.2% in the 1st quarter. Millennium Management LLC now owns 273,621 shares of the biotechnology company’s stock valued at $1,259,000 after purchasing an additional 206,088 shares in the last quarter. Northern Trust Corp boosted its stake in shares of ADMA Biologics by 618.2% in the 2nd quarter. Northern Trust Corp now owns 209,313 shares of the biotechnology company’s stock valued at $944,000 after purchasing an additional 180,170 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in shares of ADMA Biologics by 54.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 228,999 shares of the biotechnology company’s stock valued at $1,422,000 after purchasing an additional 81,003 shares in the last quarter. Institutional investors own 55.07% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.